vp-india-2026-sep-oct

myopia progression and axial elongation in the atropine group than in the placebo group. The UK setting adds another perspective to the evidence base, much of which has historically come from Asian populations. At the same time, atropine is not a universal solution. Age, progression rate, concentration, tolerability and individual circumstances all need to be considered. IS COMBINATION TREATMENT THE NEXT STEP? As treatment options increase, researchers are also examining whether different approaches can work together. A study published on 25 September 2026 investigated 0.05% atropine as an additional treatment for children who continued to progress while wearing Defocus Incorporated Multiple Segments spectacle lenses. The findings add to emerging research around combining optical and pharmacological approaches. However, the study was a retrospective matched cohort study rather than a randomised clinical trial, so its findings require appropriate interpretation. The research nevertheless reflects a broader shift towards adapting treatment according to individual progression and response. A MORE INDIVIDUAL APPROACH Perhaps the biggest change in myopia management is the move towards individualised care. There is no single intervention that will suit every child. A seven-year-old with rapidly progressing myopia presents a different challenge from a 13-year-old whose prescription has remained relatively stable. Age, refractive error, rate of progression, axial length, family history, lifestyle, treatment preferences and compliance can all influence clinical decisions. For the optical professional, this means the role is changing too. Accurate refraction, appropriate correction and good dispensing remain fundamental, but they now sit within a longer conversation about monitoring and managing progression. The question is no longer simply, “What prescription does this child need?” It is increasingly, BEYOND LENSES AND DROPS Orthokeratology and multifocal soft contact lenses remain important areas of myopia control research, while newer technologies continue to emerge. Repeated low-intensity red light therapy is one example. Longer-term research is examining its potential alongside approaches such as orthokeratology, while the September 2026 review identifies it as an emerging area requiring further study. As more technologies enter the market, practitioners need to distinguish between established evidence and promising but developing research. Myopia management is also not limited to products. Time outdoors remains part of the wider conversation around childhood myopia. While it does not replace clinical intervention for a progressing child, encouraging outdoor time can form part of a broader approach to managing risk. “How is this child's myopia changing, and what can we do about it?” For the optical professional, the prescription is still where the conversation begins. Increasingly, however, it is no longer where the conversation ends. 46 VISION PLUS INDIA EDITION